We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current BGLC market cap is 4.38M. The company's latest EPS is USD -0.1463 and P/E is -1.57.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Revenue | 2.88M | 2.75M | 2.25M | 2.58M | 2.7M |
| Operating Income | -155k | -2.53M | 257k | -79k | 259k |
| Net Income | -259k | -2.61M | 307k | -104k | 199k |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 12.28M | 13.43M | 11.11M | 10.26M |
| Operating Income | 1.27M | 1.06M | -291k | -2.59M |
| Net Income | 1.09M | 752k | -356k | -2.63M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Total Assets | 7.9M | 11.47M | 11.4M | 11.16M | 11.14M |
| Total Liabilities | 1.94M | 1.78M | 1.74M | 1.82M | 1.59M |
| Total Equity | 5.96M | 9.69M | 9.66M | 9.34M | 9.55M |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 10.12M | 9.57M | 8.74M | 11.4M |
| Total Liabilities | 3.45M | 2.39M | 2.08M | 1.74M |
| Total Equity | 6.66M | 7.18M | 6.67M | 9.66M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | ||
| Operating | -140k | -1.04M | -1.3M | -34k | -704k |
| Investing | -8k | -368k | -383k | 24k | 107k |
| Financing | -4k | 5.74M | 5.76M | 24k | 197k |
| Year End December 30 2023 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 553k | 9k | 544k | -1.3M |
| Investing | 1.32M | -491k | -451k | -383k |
| Financing | -5k | -28k | 116k | 5.76M |
| Market Cap | 4.38M |
| Price to Earnings Ratio | -1.57 |
| Price to Sales Ratio | 0.4 |
| Price to Cash Ratio | 1.58 |
| Price to Book Ratio | 0.43 |
| Dividend Yield | - |
| Shares Outstanding | 17.97M |
| Average Volume (1 week) | 45.89k |
| Average Volume (1 Month) | 1.58M |
| 52 Week Change | -60.05% |
| 52 Week High | 3.39 |
| 52 Week Low | 0.216 |
| Spread (Intraday) | 0.03 (13.83%) |
| Company Name | BioNexus Gene Lab Corporation |
| Address |
1309 coffeen avenue ste 1200 sheridan, wyoming 82801 |
| Website | https://www.bionexusgenelab.com |
| Industry | medical laboratories (8071) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
